{"id":926132,"date":"2026-01-12T09:02:58","date_gmt":"2026-01-12T14:02:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/"},"modified":"2026-01-12T09:02:58","modified_gmt":"2026-01-12T14:02:58","slug":"iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/","title":{"rendered":"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025"},"content":{"rendered":"<h2>\nDemonstrating continued revenue growth, operational efficiencies and positive cash flow<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>MOUNTAIN VIEW, Calif., Jan.  12, 2026  (GLOBE NEWSWIRE) &#8212; Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026.<\/p>\n<p>\n        <strong>Fourth Quarter 2025 Results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Total revenue is expected to be between\u00a0$14.6 million\u00a0and\u00a0$14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%<\/li>\n<li style=\"margin-bottom:8pt\">Achieved positive cash flow in the fourth quarter<\/li>\n<li style=\"margin-bottom:8pt\">Sold 15,800 Cyclo G6<sup>\u00ae<\/sup>\u00a0probes compared to 13,300 in the prior year quarter<\/li>\n<li style=\"margin-bottom:8pt\">Sold 44 Cyclo G6 Glaucoma Laser Systems, compared to 47 in the prior year quarter<\/li>\n<\/ul>\n<p>\n        <strong>Full Year 2025 Results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Total revenue is expected to be between\u00a0$52.5 million\u00a0and\u00a0$52.7 million compared to\u00a0$48.7 million\u00a0in 2024, representing year-over-year growth of 8%<\/li>\n<li style=\"margin-bottom:8pt\">The company expects to achieve positive adjusted EBITDA in 2025<\/li>\n<li style=\"margin-bottom:8pt\">Sold 57,700 Cyclo G6<sup>\u00ae<\/sup>\u00a0probes, compared to 55,400 in the prior year<\/li>\n<li style=\"margin-bottom:8pt\">Sold 133 Cyclo G6<sup>\u00ae<\/sup> Glaucoma Laser Systems compared to 125 in the prior year<\/li>\n<\/ul>\n<p>\u201cIn 2025, we strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales,\u201d said Patrick Mercer, President and CEO of IRIDEX. \u201cWhen we set and communicated our goals for 2025, we were clear about what we intended to accomplish\u2014and in 2025 we delivered. The actions we took drove a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA. We achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025.\u201d<\/p>\n<p>These preliminary results are based on management&#8217;s initial analysis of operations for the quarter and year ended\u00a0January 3, 2026, and are subject to the completion of the Company\u2019s year-end financial reporting processes, further internal review, potential adjustments, and audit by the Company&#8217;s external auditors.\u00a0<\/p>\n<p>\n        <strong>About\u00a0Iridex Corporation\u00a0<\/strong><br \/>\n        <br \/>Iridex Corporation\u00a0is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company\u2019s proprietary\u00a0MicroPulse<sup>\u00ae<\/sup>\u00a0technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex\u2019s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases.\u00a0Iridex\u00a0products are sold in\u00a0the United States\u00a0through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the\u00a0Iridex\u00a0website at\u00a0<u>www.iridex.com<\/u>.<\/p>\n<p>MicroPulse<sup>\u00ae<\/sup> is a registered trademark of\u00a0Iridex Corporation, Inc.\u00a0in\u00a0the United States,\u00a0Europe\u00a0and other jurisdictions.\u00a0\u00a0\u00a9 2025\u00a0Iridex Corporation.\u00a0 All rights reserved.<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning continued revenue growth, operational efficiencies, positive cash flow, and financial and operating results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the \u201cRisk Factors\u201d section of Iridex\u2019s most recent Annual Report on Form 10-K, as well as in Iridex\u2019s other reports filed with or furnished to the United States Securities and Exchange Commission (\u201cSEC\u201d), available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UFuCqmP_w_GEp_SZoCiGlEK_EidhjQ74CRTg8DBnGVxohRHy1MNbxATTmACip2oLRwFwOOL4LfW1akQoSb089Rc5fIGtWbsTk-uLgSDuun1ZJ_Rt_IIZSfULzyVcyQr5uBXG1lqU3e0FjXW4wkU43_l16qg5bL5eYWNkvDBTVWYoorHcA6UpaxaMqBmQwLQpFqY7D3YhiCDjQoz8G69aeBR9HSNVJmF3PB7fBA0_0UWxJX1lOeeR2vLj5Gg2BiB8CBwa8wXMImQP1F-JPj3Pgpct0vob-bNrnJgoymFsHhVXIu17owK8H-O-PipiWJiuVG_inGLSGX567Eo89UIacG86EaC9xtDFrtybyKjFOArdMup5cGU_YWp9SLm_8pE_lmTV59Ib8ctqNISZ5zQSLuwEtxQZLPB9vEyNDjNLBd0eAfgmEAIeiMckm6vKiUWUTDDpAnt6ya1Ko5RIhDBZ7iunumIaGiEZm-YJwLa0gTudDYAh75pbzoXmWk0ELuJMfWleobiEbtHUSobF7pQTmPhy40mIEewlgjXkKYDiNvSmHJ17Q4ChnabX7zpRe0V_x2UUSeq38_xNVOdIlfBOk1CRuFWYO_u7IS9qwVFDefA=\" rel=\"nofollow\" target=\"_blank\"><u>www.sec.gov<\/u><\/a>. Forward-looking statements contained in this announcement are made as of this date and will not be updated.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>Philip Taylor<br \/>Gilmartin Group<br \/><u>investors@iridex.com<\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTdlMmZiMTItN2VjNi00NmZlLWJkOWQtNGFmMjAzYjc1YjhkLTEwMjA2ODItMjAyNi0wMS0xMi1lbg==\/tiny\/IRIDEX-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) &#8212; Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results Total revenue is expected to be between\u00a0$14.6 million\u00a0and\u00a0$14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17% Achieved positive cash flow in the fourth quarter Sold 15,800 Cyclo G6\u00ae\u00a0probes compared to 13,300 in the prior year quarter Sold 44 Cyclo G6 Glaucoma Laser &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926132","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) &#8212; Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results Total revenue is expected to be between\u00a0$14.6 million\u00a0and\u00a0$14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17% Achieved positive cash flow in the fourth quarter Sold 15,800 Cyclo G6\u00ae\u00a0probes compared to 13,300 in the prior year quarter Sold 44 Cyclo G6 Glaucoma Laser &hellip; Continue reading &quot;Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:02:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025\",\"datePublished\":\"2026-01-12T14:02:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/\",\"name\":\"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=\",\"datePublished\":\"2026-01-12T14:02:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/","og_locale":"en_US","og_type":"article","og_title":"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - Market Newsdesk","og_description":"Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) &#8212; Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results Total revenue is expected to be between\u00a0$14.6 million\u00a0and\u00a0$14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17% Achieved positive cash flow in the fourth quarter Sold 15,800 Cyclo G6\u00ae\u00a0probes compared to 13,300 in the prior year quarter Sold 44 Cyclo G6 Glaucoma Laser &hellip; Continue reading \"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-12T14:02:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025","datePublished":"2026-01-12T14:02:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/","name":"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=","datePublished":"2026-01-12T14:02:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzI1MSM3MzU0MDYxIzIwMDkxMDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-year-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926132"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926132\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}